AJ Burban
Chief Financial Officer
Replay available
Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Call
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Q2 2025 earnings conference call, held 2025-08-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Linda Marban
President and Chief Executive Officer
Ted Denhoff
Analyst, Piper Sandler
Leland Gershow
Analyst, Oppenheimer
Joe Pantginis
Analyst, H.C. Wainwright
Kristen Kluska
Analyst, Cantor Fitzgerald
Madison Elsady
Analyst, B. Riley Securities
Katherine Novak
Analyst, JonesTrading
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Capricor Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.894 Good afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics Second 00:00:03.894 -- 00:00:08.879 Quarter 2025 Conference Call. At this time, all participant lines are in lease and only 00:00:08.879 -- 00:00:14.044 mode. Following the presentation, we will conduct a question and answer session. 00:00:14.044 -- 00:00:17.286 If at any time during this call you require immediate assistance, please press the star 00:00:17.286 -- 00:00:23.572 zero for the operator. This call is being recorded on Monday, August 11th, 2025. 00:00:23.572 -- 00:00:27.636 I would now like to turn the conference over to CFO, AJ Burpan, for the forward-looking 00:00:27.636 -- 00:00:31.017 statements. Please go ahead. 00:00:32.465 -- 00:00:36.039 Thank you and good afternoon. Everyone before we start, I would like to state that we 00:00:36.039 -- 00:00:39.935 will be making certain forward looking statements during today's presentation. 00:00:39.935 -- 00:00:44.411 These statements may include. Statements regarding, among other things, the efficacy 00:00:44.411 -- 00:00:48.618 safety intended utilization of our product candidates, our future research and development 00:00:48.618 -- 00:00:53.406 plans, including our anticipated conduct and timing of preclinical and clinical studies. 00:00:53.406 -- 00:00:57.653 Our enrollment of patients in our clinical studies, our plans to present a report, additional 00:00:57.653 -- 00:01:02.200 data, our plans regarding regulatory filings, potential regulatory developments involving 00:01:02.200 -- 00:01:07.126 our product candidates. potential regulatory inspections, revenue and reimbursement estimates, 00:01:07.126 -- 00:01:11.431 projected terms of definitive agreements, manufacturing capabilities, poten...